Results 301 to 310 of about 713,346 (360)
Some of the next articles are maybe not open access.
Current Medicinal Chemistry-Cardiovascular & Hematological Agents, 2004
Type 1 receptors (AT1) for the peptide hormone angiotensin II play a crucial role in the cardiovascular homeostasis. In this regard, several selective, orally active non-peptide antagonists have been developed for the treatment of hypertension and congestive heart failure.
I, Verheijen +3 more
openaire +2 more sources
Type 1 receptors (AT1) for the peptide hormone angiotensin II play a crucial role in the cardiovascular homeostasis. In this regard, several selective, orally active non-peptide antagonists have been developed for the treatment of hypertension and congestive heart failure.
I, Verheijen +3 more
openaire +2 more sources
Neurokinin receptor antagonists
Expert Opinion on Investigational Drugs, 2000Studies on tachykinin peptides and the corresponding neurokinin receptors (NKr) have increased dramatically recently due to the discovery of selective, orally-active, metabolically stable and sometimes CNS penetrating NKr antagonists. After demonstrating the potential use for NKr antagonists in animal models, some compounds have recently progressed ...
V, Leroy, P, Mauser, Z, Gao, N P, Peet
openaire +2 more sources
Prolactin Receptor Antagonists
Endocrine, 1998Most prolactin (PRL) in the circulation is produced by the pituitary. However, a wide variety of traditional target tissues of the hormone have also been shown to produce their own prolactin. The amount produced per cell is low, but may well be sufficient for autocrine/paracrine activity.
C B, Kuo, D, Coss, A M, Walker
openaire +2 more sources
Mineralocorticoid Receptor Antagonists
2019Two mineralocorticoid receptor antagonists, spironolactone and eplerenone, are currently approved by the FDA. Several non-steroid based ligands are in clinical trials for indications including heart failure, hypertension and diabetic kidney disease, and even more structurally distinct chemical series are reported in the literature with preclinical data
Anneli, Nordqvist, Kenneth L, Granberg
openaire +2 more sources
Pharmaceutical Patent Analyst, 2012
The orexin neuropeptides bind to two G protein-coupled receptors, orexin-1 and -2. Small-molecule antagonism of the receptors has potential therapeutic utility in a number of areas, most notably insomnia, for which the most advanced dual orexin receptor antagonist has now completed clinical trials.
openaire +2 more sources
The orexin neuropeptides bind to two G protein-coupled receptors, orexin-1 and -2. Small-molecule antagonism of the receptors has potential therapeutic utility in a number of areas, most notably insomnia, for which the most advanced dual orexin receptor antagonist has now completed clinical trials.
openaire +2 more sources
Vasopressin Receptor Antagonists
Current Hypertension Reports, 2015Arginine vasopressin (AVP) is the principal hormone involved in regulating the tonicity of body fluids. Less appreciated is the role that AVP plays in a variety of other physiologic functions including glucose metabolism, cardiovascular homeostasis, bone metabolism, and cognitive behavior.
openaire +2 more sources
Cholecystokinin receptor antagonists
American Journal of Physiology-Gastrointestinal and Liver Physiology, 1984Since 1979 three classes of cholecystokinin receptor antagonists have been described: 1) derivatives of cyclic nucleotides, 2) derivatives of amino acids, and 3) C-terminal fragments or partial sequences of cholecystokinin. These various antagonists share a number of common features, such as their specific, reversible, and competitive actions, but ...
J D, Gardner, R T, Jensen
openaire +2 more sources
Muscarinic Receptor Antagonists
2016Parasympathetic activity is increased in patients with chronic obstructive pulmonary disease (COPD) and asthma and appears to be the major reversible component of airway obstruction. Therefore, treatment with muscarinic receptor antagonists is an effective bronchodilator therapy in COPD and also in asthmatic patients.
Maria Gabriella, Matera, Mario, Cazzola
openaire +2 more sources
Mineralocorticoid receptor antagonists
Current Hypertension Reports, 2007With an increasingly aging population, the need for effective treatment of cardiovascular diseases (eg, heart failure, hypertension, and ischemic heart disease) cannot be overemphasized. The vital importance of mineralocorticoid receptor antagonists for treating cardiovascular conditions has only been appreciated in the last decade. The re-emergence of
Parthasarathy, Hari Krishnan +1 more
openaire +3 more sources
Seminars in Thrombosis and Hemostasis, 1996
Thrombin's proteolytically activated "tethered-ligand" receptor is widely expressed and mediates many of thrombin's actions on cells. Its central role in thrombin-stimulated human platelet activation and vascular smooth muscle proliferation as well as location in atherosclerotic plaques suggests receptor involvement in arterial thrombosis and ...
openaire +2 more sources
Thrombin's proteolytically activated "tethered-ligand" receptor is widely expressed and mediates many of thrombin's actions on cells. Its central role in thrombin-stimulated human platelet activation and vascular smooth muscle proliferation as well as location in atherosclerotic plaques suggests receptor involvement in arterial thrombosis and ...
openaire +2 more sources